Medtronic‘s (NYSE: MDT) third-fiscal-quarter revenue chart would make a good preschool test for finding the outlier. (Hint: Look for the parentheses.)
| Segment | Sales (in Millions) | Increase (Decrease) at Constant Currencies |
|---|---|---|
| Cardiac rhythm disease management | $1,243 | 2% |
| Spinal | $842 | (1%) |
| Cardiovascular | $722 | 21% |
| Neuromodulation | $394 | 8% |
| Diabetes | $311 | 8% |
| Surgical technologies | $239 | 12% |
| Physio-control | $100 | 8% |
To read more please CLICK HERE
Source: Company press release.
